Vigabatrin

CAS 60643-86-9 9 FDA-DMF suppliersSmall Molecule

Overview

Vigabatrin is an antiepileptic drug used as an adjunctive therapy for patients with refractory complex partial seizures. It irreversibly inhibits the enzyme gamma-aminobutyric acid transaminase (GABA-T), leading to increased levels of GABA in the brain.

API suppliers (4)

Suppliers of Vigabatrin backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

  • DPT Laboratories, Ltd.United States1 active DMF
  • DPT Laboratories, Ltd.United States1 active DMF
  • DPT Laboratories, Ltd.United States1 active DMF
  • DPT Laboratories, Ltd.United States1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (21 approved US products), the latest listed US patent on Vigabatrin expires 7 Jun 2043. Generic API sourcing typically opens up once these lapse.

Therapeutic areas

EpilepsyNeurology

Related APIs

Levetiracetam
37 suppliers
Lacosamide
33 suppliers
Brivaracetam
22 suppliers
Cannabidiol
19 suppliers
Felbamate
15 suppliers
Rufinamide
11 suppliers
Primidone
10 suppliers
Stiripentol
7 suppliers

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.

Start free trialBook a demo